A

few weeks ago, a group of Democrats in both houses of Congress introduced the Improving Access to Affordable Prescription Drugs Act, a 129-page bill designed to lower drug prices while increasing innovation and cracking down on pharmaceutical company abuses (my thoughts on the bill are here).

There’s one provision that hasn’t gotten enough attention: the creation of a prize fund for new antibiotics.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting article, thanks. With regard to the two points you highlight at the end, conditioning the prize on (1) making the product available at a low price, and (2) waiving IPRs (and other forms of exclusivity), readers may wonder why the second is necessary if the first is in effect. That is, one might ask, “if the winner of the prize can’t set a high price, why should I care any more if she still has a patent?” It would make this essay more useful if you were to explain that too. (To be clear, I think there’s a good answer to the question, I just wish it were included here, as it may not be obvious to many readers).

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.